Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline’s study shows efficacy of reduced Bexsero dosage

GlaxoSmithKline’s study shows efficacy of reduced Bexsero dosage

17th May 2016

GlaxoSmithKline has announced new clinical trial data showing how its meningococcal group B vaccine Bexsero could be safely used with a reduced dosage.

The phase IIIb study, entitled V72_28, aimed to compare and evaluate the safety and immunogenicity of different Bexsero dosing schedules in infants and young children, with results presented at the annual meeting of the European Society for Paediatric Infectious Diseases.

Bexsero was able to meet its primary and secondary endpoints, showing comparable immune responses and safety in infants receiving a reduced schedule of two primary doses of the vaccine plus a booster dose compared to those receiving the current EU-approved schedule of three primary doses and a booster.

These study results may support a reduced dosing schedule, which could mean fewer shots for infants.

Dr Thomas Breuer, chief medical officer for vaccines at GlaxoSmithKline, said: "We look forward to the important additional data that will come out of the UK routine infant immunisation programme with Bexsero, which may enable countries to have different scheduling options in the future."

Bexsero is currently licensed in more than 35 countries.ADNFCR-8000103-ID-801818545-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.